Green Cross Expands Biologics Business to North America
Green Cross, a South Korean biopharmaceutical company, has announced that it will build a new biologics manufacturing facility in Canada, as part of the company’s efforts to expand its biologics business to North America.
The plant will be located in Montréal, Québec. The company anticipates the new plant will be the Canada’s only plasma-fractionation facility.
Green Cross Biotherapeutics (GCBT), a new subsidiary of Green Cross, has signed an agreement on the 4th of April with Investissement Québec to receive a financial commitment totalling CAD 25 million for the proposed project.
Green Cross projects the total capital expenditure at the new site to exceed CAD 180 million over the next 5 years.
"This investment will demonstrate our long-term dedication to the patients in the North American region who rely on plasma-derived medicines, and will create hundreds of full-time positions in Montréal" said Il-sup Huh, Chairman and CEO of Green Cross.
Construction will begin later this year, with commercial production scheduled to begin in 2019. The new facility will have the capacity to fractionate up to 1 million litres of plasma a year.
The Green Cross products that will be manufactured in Canada includes Intravenous Immunoglobulin (IVIG) for patients with infectious and immune disorders and albumin products to treat burns and clotting factor for bleeding disorders.
GCBT has also signed an agreement on the same day with Héma-Québec to supply Intravenous Immunoglobulin (IVIG) as soon as production begins at the new plant. With this agreement GCBT will supply IVIGs to Héma-Québec for the period of 5 years with 3 year or more renewal options.
“North America is an extremely important market for us. The market for IVIG particularly is booming with Canada one of the world's highest per capita users, and North America constitutes more than 40% of the global plasma-products market" said Young-Ho Kim, President of GCBT. "We expect the annual sales will reach up to CAD 300 million over the next 10 years."
"We look forward to delivering the safe and high-quality medicines to Canadians, and we will make our best efforts to provide our plasma based products to patients in other parts of the region as well."
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance